• Something wrong with this record ?

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders

K. Polgarova, K. Vargova, V. Kulvait, N. Dusilkova, L. Minarik, Z. Zemanova, M. Pesta, A. Jonasova, T. Stopka,

. 2017 ; 8 (67) : 111966-111978. [pub] 20171206

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18010077

Grant support
NV16-27790A MZ0 CEP Register

Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized massive parallel sequencing of 54 genes previously associated with MDS/AML pathogenesis. Serial sampling before and during AZA therapy of 38 patients (reaching median overall survival 24 months (Mo) with 60% clinical responses) identified 116 somatic pathogenic variants with allele frequency (VAF) exceeding 5%. High accuracy of data was achieved via duplicate libraries from myeloid cells and T-cell controls. We observed that nearly half of the variants were stable while other variants were highly dynamic. Patients with marked decrease of allelic burden upon AZA therapy achieved clinical responses. In contrast, early-progressing patients on AZA displayed minimal changes of the mutation pattern. We modeled the VAF dynamics on AZA and utilized a joint model for the overall survival and response duration. While the presence of certain variants associated with clinical outcomes, such as the mutations ofCDKN2Awere adverse predictors whileKDM6Amutations yield lower risk of dying, the data also indicate that allelic burden volatility represents additional important prognostic variable. In addition, preceding 5q- syndrome represents strong positive predictor of longer overall survival and response duration in high risk MDS patients treated with AZA. In conclusion, variants dynamics detected via serial sampling represents another parameter to consider when evaluating AZA efficacy and predicting outcome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010077
003      
CZ-PrNML
005      
20180405103453.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.22957 $2 doi
035    __
$a (PubMed)29340104
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Polgarova, Kamila $u Department Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic. Department of Haematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.
245    10
$a Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders / $c K. Polgarova, K. Vargova, V. Kulvait, N. Dusilkova, L. Minarik, Z. Zemanova, M. Pesta, A. Jonasova, T. Stopka,
520    9_
$a Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized massive parallel sequencing of 54 genes previously associated with MDS/AML pathogenesis. Serial sampling before and during AZA therapy of 38 patients (reaching median overall survival 24 months (Mo) with 60% clinical responses) identified 116 somatic pathogenic variants with allele frequency (VAF) exceeding 5%. High accuracy of data was achieved via duplicate libraries from myeloid cells and T-cell controls. We observed that nearly half of the variants were stable while other variants were highly dynamic. Patients with marked decrease of allelic burden upon AZA therapy achieved clinical responses. In contrast, early-progressing patients on AZA displayed minimal changes of the mutation pattern. We modeled the VAF dynamics on AZA and utilized a joint model for the overall survival and response duration. While the presence of certain variants associated with clinical outcomes, such as the mutations ofCDKN2Awere adverse predictors whileKDM6Amutations yield lower risk of dying, the data also indicate that allelic burden volatility represents additional important prognostic variable. In addition, preceding 5q- syndrome represents strong positive predictor of longer overall survival and response duration in high risk MDS patients treated with AZA. In conclusion, variants dynamics detected via serial sampling represents another parameter to consider when evaluating AZA efficacy and predicting outcome.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vargova, Karina $u Department of Pathophysiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kulvait, Vojtech $u Department Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic.
700    1_
$a Dusilkova, Nina $u Department Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic. Department of Pathophysiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Minarik, Lubomir $u Department Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic. Department of Haematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Zemanova, Zuzana $u Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Pesta, Michal $u Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic.
700    1_
$a Jonasova, Anna $u Department of Haematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Stopka, Tomas $u Department Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic. Department of Haematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 67 (2017), s. 111966-111978
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29340104 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180405103534 $b ABA008
999    __
$a ind $b bmc $g 1287562 $s 1006889
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 67 $d 111966-111978 $e 20171206 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NV16-27790A $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options